India

Population 2018  1 353 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>2 690 (1 840–3 700)</td>
<td>199 (136–273)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>92 (63–126)</td>
<td>6.8 (4.6–9.3)</td>
</tr>
<tr>
<td>MDR/RR-TB incidenceº</td>
<td>130 (77–198)</td>
<td>9.6 (5.7–15)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>440 (410–470)</td>
<td>32 (30–35)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>8.7 (5.7–15)</td>
<td>0.72 (0.42–1.1)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases 2.8% (2.3–3.5)
Previously treated cases 14% (14–14)

TB case notifications, 2018

Total new and relapse 1 994 000
- % tested with rapid diagnostics at time of diagnosis 50%
- % with known HIV status 72%
- % pulmonary 82%
- % bacteriologically confirmedºº 57%
- % children aged 0–14 years 6%
- % women 34%
- % men 60%

Total cases notified 2 155 894

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018 74% (54–110)
TB patients facing catastrophic total costs
TB case fatality ratio (estimated mortality/estimated incidence), 2018 17% (12–24)

TB/HIV care in new and relapse TB patients, 2018

Number (%) Patients with known HIV status who are HIV-positive
- on antiretroviral therapy 49 047 3%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ººº
- New cases 46%
- Previously treated cases 91%

Laboratory-confirmed cases* MDR/RR-TB: 58 347, XDR-TB: 3 400
Patients started on treatment** MDR/RR-TB: 46 569, XDR-TB: 2 724

MDR/RR-TB cases tested for resistance to second-line drugs 38 236

Treatment success rate and cohort size

Success Cohort
New and relapse cases registered in 2017 81% 1 568 392
Previously treated cases, excluding relapse, registered in 2017 96% 146 982
HIV-positive TB cases registered in 2017 71% 31 213
MDR/RR-TB cases started on second-line treatment in 2016 48% 33 197
XDR-TB cases started on second-line treatment in 2016 30% 2 464

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment 17%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 26% (24–28)

TB financing, 2019

National TB budget (US$ millions) 583
Funding source: 77% domestic, 23% international, 0% unfunded

º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-03-20 Data: www.who.int/tb/data